From Microdosing to Mystical Experiences with Julianne Keu
Similar Posts
MindMed To Deliver Psychedelics Directly To The Brain? (MMED / MNMD)
MindMed (MMED :NEO), (MNMD:NASDAQ), (MMQ: FRA) is testing the delivery of psychedelics compounds directly to the brain!?
What is the best way to take a psychedelic medicine? Is it in a format of a pill, a film strip which dissolves under the tongue, or maybe an injection? These are the standard delivery methods we’re all familiar with.
But what if we could deliver a psychedelic medicine directly to the brain, and thus negate any potentially negative side effects of the drug interacting with the body?
Answering this question is the purpose of a new MindMed partnership.
In this episode, we’ll explore MindMed’s new partnership with Nextage Therapeutics, their Brain Targeting Liposome System (BTLS), and it’s applications.
Enjoy the episode!
Link:
https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Website: https://thepsychedelicinvestor.com/
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindmedNews
MindMed Expands MICRODOSING trials (BIG MMED/MMEDF stock UPDATE)
In today’s episode “MindMed Expands Microdosing Trials”, we’ll discuss a Big MindMed Stock Update.
On January 12th, MindMed ticker symbol (NEO: MMED ) and (OTC:MMEDF) put out a Press Release entitled MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers. In other words, MindMed is expanding its LSD microdosing studies from just looking at how they can help those with adult ADHD, to how they could affect a more general population. This is BIG news the MindMed team and us shareholders.
As I mentioned in one of our previous episodes : “Why I’m More Excited About MindMed’s 18-MC than its LSD treatments”, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. And If these trials come back successful, it’ll be the beginning of more LSD microdosing studies for MindMed.
In this episode, we will do three things:
1:We’ll read the Press Release and discuss what it means, in layman’s terms
2: We’ll enter the Speculation Zone to discuss the potential effects of this move
3: We’ll discuss how this expansion affects MindMed stock as an investment
So, what does this all mean for investors?
Can we assume that MindMed’s LSD microdosing to treat ADHD trial is going well? This, even without the new trials, would be very good news for us long term investors. Moreover, this new study shows that MindMed is continuing to expand their potential product pipeline which will also look great for the MMED/ MMEDF Stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Bad NEWS for NUMI, FieldTrip and J&J || Esketamine to Treat DEPRESSION Study Results And More
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG esketamine study results, new 5MEO-DMT tests and Updates on the decriminalization efforts in California and Texas.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. We’ll cover some interesting and maybe disappoint results coming from a study designed to determine whether esketamine can treat depression and their implications on some companies such as Numinus Wellness (NUMI), Field Trip Health ( FTRP) and Johnsons & Johnson (JNJ)
2. Study looking at the creativity benefits of taking psilocybin
3. Compass Pathways (CMPS) has amazing new price targets
4. First ever clinical trial testing the safety profile of a compound called 5MEO – DMT
5. A couple of updates on decriminalization efforts
Timestapms:
0:00 – Intro
1:33 – Likelihood of Adverse events from Nasal Esketamine : Implications for Numinus, JNJ and Fieldtrip Health
6:07 – Psilocybin’s effects on creativity in a new placebo-controlled neuroimaging and it’s effects on MindMed (MMED/MMEDF), Compass Pathways (CMPS), Mydecine (MYCO) , Numinus ( NUMI)
11:25 – Researchers to team up to produce the first ever 5-meo-DMT Psychedelic Training Program
12:28 – California bill To Legalize Possession of Psychedelics Clears Second Senate Committee
14:26 – Rick Perry supports the Texas Capital to study psychedelic drugs from PTSD in veterans.
I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #Numi #Mindmed
Mapping the Brain on Psychedelics & the Complexity Science Perspective with Manesh Girn
Psychedelic neuroscientist, Manesh Girm, talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI, FTPRF, ATAI & CYBN]
In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin (CYBN) & Fieldtrip Health (FTPRF).
I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the EFSE so that mindmed news is not in this episode.
We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Timestamps:
0:00 – Intro
0:43 – Australian federal government funds psychedelic research to treat mental illnesses
2:19 – Rhode Island wants to decriminalize all drugs
3:54 – New York Bill to decriminalize psilocybin mushrooms
6:34 – MindMed stock updates ( mmed, mmedf, mmq )
8:17 – Compass Pathways stock news (cmps)
8:49 – Atai Life Sciences news
12:37 – Fieldtrip Health stock news ( ftprf, ftrp)
15:04 – Numinus Wellness stock news ( NUMI, LKYSF)
16:16 – Cybin stock news ( cybn, clxpf)
18:18 General psychedelics discussion
So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks